Haleon (LON:HLN) Shares Up 0.5% – Should You Buy?

Haleon plc (LON:HLN) shares traded up 0.5% during trading on Tuesday . The stock traded as high as GBX 373.70 and last traded at GBX 369.90. 30,502,482 shares changed hands during mid-day trading, an increase of 14% from the average session volume of 26,647,273 shares. The stock had previously closed at GBX 368.20.

Analyst Ratings Changes

A number of analysts recently weighed in on HLN shares. JPMorgan Chase & Co. decreased their price target on Haleon from GBX 335 to GBX 315 and set an “underweight” rating on the stock in a research note on Thursday, June 25th. Royal Bank Of Canada increased their price objective on Haleon from GBX 370 to GBX 390 and gave the stock a “sector perform” rating in a research report on Tuesday, August 11th. Jefferies Financial Group reissued a “buy” rating and issued a GBX 400 target price on shares of Haleon in a report on Friday, July 31st. Berenberg Bank boosted their target price on shares of Haleon from GBX 512 to GBX 514 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Finally, Deutsche Bank Aktiengesellschaft upped their price target on shares of Haleon from GBX 325 to GBX 335 and gave the stock a “sell” rating in a research note on Friday, July 31st. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Haleon currently has an average rating of “Hold” and an average target price of GBX 399.

Haleon Stock Performance

The stock’s 50-day moving average price is GBX 363.46 and its 200-day moving average price is GBX 360.34. The company has a debt-to-equity ratio of 50.38, a quick ratio of 0.93 and a current ratio of 0.69. The company has a market capitalization of £31.50 billion, a price-to-earnings ratio of 19.76, a P/E/G ratio of 1.49 and a beta of 0.24.

Haleon (LON:HLN) last announced its quarterly earnings results on Thursday, July 30th. The company reported GBX 8.60 EPS for the quarter. Haleon had a return on equity of 9.89% and a net margin of 14.55%. As a group, equities research analysts expect that Haleon plc will post 19.5033282 earnings per share for the current year.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.